WO2004038411A3 - Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases Download PDF

Info

Publication number
WO2004038411A3
WO2004038411A3 PCT/EP2003/011747 EP0311747W WO2004038411A3 WO 2004038411 A3 WO2004038411 A3 WO 2004038411A3 EP 0311747 W EP0311747 W EP 0311747W WO 2004038411 A3 WO2004038411 A3 WO 2004038411A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
ensadin
gene
neurodegenerative diseases
diagnostic
Prior art date
Application number
PCT/EP2003/011747
Other languages
French (fr)
Other versions
WO2004038411A2 (en
Inventor
Johannes Pohlner
Der Kammer Heinz Von
Rainer Hipfel
Original Assignee
Evotec Neurosciences Gmbh
Johannes Pohlner
Der Kammer Heinz Von
Rainer Hipfel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Johannes Pohlner, Der Kammer Heinz Von, Rainer Hipfel filed Critical Evotec Neurosciences Gmbh
Priority to AU2003279312A priority Critical patent/AU2003279312A1/en
Publication of WO2004038411A2 publication Critical patent/WO2004038411A2/en
Publication of WO2004038411A3 publication Critical patent/WO2004038411A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

The present invention discloses the differential expression of a gene coding for Ensadin-0289 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the Ensadin-0289 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.
PCT/EP2003/011747 2002-10-24 2003-10-23 Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases WO2004038411A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003279312A AU2003279312A1 (en) 2002-10-24 2003-10-23 Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42073702P 2002-10-24 2002-10-24
EP02023872 2002-10-24
US60/420,737 2002-10-24
EP02023872.1 2002-10-24

Publications (2)

Publication Number Publication Date
WO2004038411A2 WO2004038411A2 (en) 2004-05-06
WO2004038411A3 true WO2004038411A3 (en) 2004-06-17

Family

ID=32178669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011747 WO2004038411A2 (en) 2002-10-24 2003-10-23 Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases

Country Status (2)

Country Link
AU (1) AU2003279312A1 (en)
WO (1) WO2004038411A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 7 February 2001 (2001-02-07), OTA T ET AL.: "Human cDNA clone (5 -primer) SEQ ID NO: 4841", XP002276508, retrieved from EBI Database accession no. AAH08006 *
DATABASE EMBL [online] EBI; 7 February 2001 (2001-02-07), OTA T. ET AL.: "Human protein sequence, SEQ ID NO:13132", XP002276507, retrieved from EBI Database accession no. AAB93639 *
DATABASE EMBL [online] XP002243747, retrieved from EBI Database accession no. ABG13413 *
DATABASE EMBL [online] XP002243748, retrieved from EBI Database accession no. AB032773 *
DATABASE EMBL [online] XP002243749, retrieved from EBI Database accession no. AB032786 *
DATABASE EMBL [online] XP002276515, retrieved from EBI Database accession no. ABL69604 *
DATABASE EMBL [online] XP002276516, retrieved from EBI Database accession no. ABL63823 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
AU2003279312A1 (en) 2004-05-13
AU2003279312A8 (en) 2004-05-13
WO2004038411A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2004043226A3 (en) Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2005085472A3 (en) Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
ATE464567T1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN ALZHEIMER'S DISEASE AND RELATED NEURODEGENERATIVE DISEASES
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2003104811A3 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2005071418A3 (en) Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases
WO2006008294A3 (en) Diagnostic and therapeutic use of slim3 for neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP